Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis

Hormone and Metabolic Research

Volumn 46, Issue 10, 2014, Pages 717-721

  Nakashima, S ^a   Matsui, T ^a   Takeuchi, M ^b   Yamagishi, S I ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

AGEs; diabetic nephropathy; DPP 4; linagliptin; oxidative stress; RAGE

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LINAGLIPTIN; MESSENGER RNA; STREPTOZOCIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; DIPEPTIDYL PEPTIDASE IV; IMMUNOGLOBULIN RECEPTOR; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; WESTERN BLOTTING; ANIMAL; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENETICS; HUMAN; KIDNEY; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; MALE; PURINES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC;

EID: 84929469873     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1371892     Document Type: Article

References (32)

1. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys: 2007; 48 147 157
2. Stitt A. W., Bucala R., Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann NY Acad Sci: 1997; 811 115 127
3. D'Agati V., Yan S. F., Ramasamy R., Schmidt A. M. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab: 2010; 21 50 56
4. Yamamoto Y., Kato I., Doi T., Yonekura H., Ohashi S., Takeuchi M., Watanabe T., Yamagishi S., Sakurai S., Takasawa S., Okamoto H., Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest: 2001; 108 261 268
5. Wendt T. M., Tanji N., Guo J., Kislinger T. R., Qu W., Lu Y., Bucciarelli L. G., Rong L. L., Moser B., Markowitz G. S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P. P., Stern D. M., D'Agati V. D., Schmidt A. M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol: 2003; 162 1123 1137
6. Cravedi P., Ruggenenti P., Remuzzi G. Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr Hypertens Rep: 2005; 9 430 436
7. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets: 2007; 8 952 959
8. Soldatos G., Cooper M. E. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract: 2008; 82 S75 S79
9. Abuissa H., O'Keefe J. Jr. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab: 2008; 10 1157 1166
10. Matsui T., Nishino Y., Maeda S., Takeuchi M., Yamagishi S. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells. Microvasc Res: 2011; 81 269 273
11. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des: 2005; 11 2279 2299
12. Yamagishi S., Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy - Friend or foe? Pharmacol Res: 2011; 64 187 194
13. Kim W., Egan J. M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev: 2008; 60 470 512
14. Yamagishi S., Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des: 2011; 17 4379 4385
15. Cordero O. J., Salgado F. J., Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother: 2009; 58 1723 1747
16. Yazbeck R., Howarth G. S., Abbott C. A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci: 2009; 30 600 607
17. Ishibashi Y., Matsui T., Maeda S., Higashimoto Y., Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol: 2013; 12 125
18. Ojima A., Ishibashi Y., Matsui T., Maeda S., Nishino Y., Takeuchi M., Fukami K., Yamagishi S. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol: 2013; 182 132 141
19. Maeda S., Matsui T., Yamagishi S. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol: 2012; 158 171 173
20. Sakata K., Hayakawa M., Yano Y., Tamaki N., Yokota N., Eto T., Watanabe R., Hirayama N., Matsuo T., Kuroki K., Sagara S., Mishima O., Koga M., Nagata N., Nishino Y., Kitamura K., Kario K., Takeuchi M., Yamagishi S. I. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product - receptor for advanced glycation end product axis, and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev: 2013; 29 624 630
21. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun: 2010; 391 1405 1408
22. Ishibashi Y., Nishino Y., Matsui T., Takeuchi M., Yamagishi S. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism: 2011; 60 1271 1277
23. Ojima A., Matsui T., Maeda S., Takeuchi M., Yamagishi S. Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties. Horm Metab Res: 2012; 44 501 505
24. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res: 2011; 43 731 734
25. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem: 2006; 281 20213 20220
26. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia: 1998; 41 1435 1441
27. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Takeuchi M., Makita Z. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol Med: 2002; 8 546 550
28. Yamagishi S., Nakamura K., Matsui T., Noda Y., Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des: 2008; 14 487 495
29. Ide Y., Matsui T., Ishibashi Y., Takeuchi M., Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res: 2010; 80 227 232
30. Morishita R., Yamagishi S. A diabetes treatment strategy to reduce the risk of cardiovascular events; Clinical benefits and potential of linagliptin. Immun Endoc Metab Agents Med Chem: 2013; 13 81 88
31. Soro-Paavonen A., Watson A. M., Li J., Paavonen K., Koitka A., Calkin A. C., Barit D., Coughlan M. T., Drew B. G., Lancaster G. I., Thomas M., Forbes J. M., Nawroth P. P., Bierhaus A., Cooper M. E., Jandeleit-Dahm K. A. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes: 2008; 57 2461 2469
32. Jelsing J., Vrang N., van Witteloostuijn S. B., Mark M., Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. J Endocrinol: 2012; 214 381 387